Clin Asst Prof Chan Junjie Jack

Dr Jack Chan is a Senior Consultant Medical Oncologist who practises at NCCS and KKWCH, subspecialising in gynaecological cancers and breast cancer. His research interests are clinical trials in women's cancers, being the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS.

Dr Chan is active in medical and interprofessional education as well as in professional bodies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He serves on the Japanese Society of Medical Oncology's International Steering Committee, and sat on the European Society of Medical Oncology Congress's Scientific Committee and Asian Society of Gynecologic Oncology Meeting's International Scientific Committee in 2024. Dr Chan has received accolades for his clinical, education and administrative work including Singapore Health Quality Service Awards (Star 2022), Outstanding Faculty Award 2020 and the Commendation Medal (COVID-19).

As an advocate for a personalised approach to cancer care, Dr Chan strives to support patients and their families through the cancer journey by addressing patients' medical needs and quality of life.

Dr Chan concurrently holds the appointment of Chief Quality Officer at NCCS, overseeing healthcare quality and patient safety, quality improvement, and patient experience.

• Fellow of Academy of Medicine Singapore, Chapter of Medical Oncologists, College of Physicians, 2018
• Member of Royal College of Physicians (UK); Master of Medicine (Internal Medicine) (Singapore), 2012
• Bachelor of Medicine and Bachelor of Surgery, 2008

• Vice President, Gynecologic Cancer Group Singapore 2025-2026 
• Co-opted Board Member, Chapter of Medical Oncology, College of Physicians, Academy of Medicine, Singapore 2023-2025 
• Member, Japanese Society of Medical Oncology’s International Steering Committee 2023-2026 
• Member, European Society of Medical Oncology Congress 2024 Scientific Committee 
• Member, Asian Society of Gynecologic Oncology 2024 Meeting International Scientific Committee

• The Commendation Medal (COVID-19) 2023 
• COVID-19 Resilience Medal 2023 
• Singapore Health Quality Service Award (Star) 2022 
• SingHealth Family Target Zero Harm Team Award 2021
• Singapore Health Quality Service Award (Hero) 2021 
• Residency in SingHealth Excels Outstanding Faculty Award 2020 
• Singapore Health Quality Service Award (Gold) 2020 
• SingHealth Health Manpower Development Plan Award 2019 
• Singapore Health Quality Service Award (Silver) 2019

• ETC-159-02: ETC-159 in combination with pembrolizumab in advanced MSS/pMMR ovari-an cancers (ClinicalTrials.gov Identifier: NCT06513624) (Site Principal Investigator) • MK5684-015: A multicenter, open-label, phase 2 basket study of MK 5684 in participants with selected solid tumors (Site Principal Investigator) 
• TroFuse-033/MK2870-033: A phase 3 randomized, open-label, multicenter study to compare the efficacy and safety of sacituzumab tirumotecan in combination with pembrolizumab ver-sus pembrolizumab alone as first-line maintenance treatment in participants with mismatch repair proficient endometrial cancer (National Principal Investigator)
• ASCENT-GYN-01: Study of sacituzumab govitecan versus treatment of physician's choice in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy (ClinicalTrials.gov Identifier: NCT06486441) (Site Principal Investigator) 
• NIRVANA-1: Niraparib with bevacizumab after complete cytoreduction in patients with ovarian cancer (ClinicalTrials.gov Identifier: NCT05183984) (Site Principal Investigator) 
• DOMENICA: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in a first-line advanced/metastatic setting (ClinicalTrials.gov Identifier: NCT05201547) (Site Principal Investigator)

• Ng QJ, Ee TX, Goh CSY, Lee SH, Low JEH, Lin J, Phoon JWL, Chan JJ, Chin FHX. On-cofertility care and fertility preservation in gynaecological cancer: experience from Singa-pore’s largest tertiary centre. Singapore Med J 2025 [Online ahead of print].
• Ang DJM, Bok KX, Wong SL, Li Y, Wong A, Yeo YC, Wang J, Aggarwal IM, Chan JJ. Sec-ond-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience. Gynecol On-col Rep 2025; 58:101709. 
• Tan JZC, Chan JJ, Dent RA, Tan TJ. Early triple-negative breast cancer: systemic therapy. In: Cardoso F, Tjan-Heijnen V, Božović-Spasojević I, Vaz Batista M, editors. Breast Cancer: Essentials for Clinicians Second Edition. Lugano, Switzerland: ESMO Press; 2024. p. 41-6. 
• Ang DJM, Chan JJ. Evolving standards and future directions for systemic therapies in cervi-cal cancer. J Gynecol Oncol 2024; 35(2):e65 e65. 
• Chong JH, Chang WT, Chan JJ, Tan TJY, Chan JWK, Wong M, Wong FY, Chuah CTH. The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer ther-apy-related cardiac dysfunction – a systematic review. Curr Probl Cardiol 2024; 49(3):102372. 
• Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibi-tors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Can-cer 2023; 9(1):74. 
• Ithimakin S, Parinyanitikul N, Kim SB, Yap YS, Tsang J, Soong IS, Ozaki Y, Ohno S, Ono M, Chan JJ, Cheng HCS, Dejthevaporn T; BIG-Asia Collaboration. Disparities in access to systemic treatment for breast cancer in Thailand and major Asian territories. J Breast Cancer 2022; 25(3):207-17. 
• Loo SY, Toh LP, Xie WH, Pathak E, Tan W, Ma S, Lee MY, Shatishwaran S, JZZ Yeo, Yuan J, Ho YY, EKL Peh, Muniandy M, Torta F, Chan J, Tan T, Sim YR, Tan V, Tan B, Madhukumar P, Yong WS, Ong KW, Wong CY, Tan PH, Yap YS, Deng LW, Dent R, Foo R, Wenk MR, Lee SC, Ho YS, Lim EH. Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Sci Adv 2021; 7(41):eabh2443. 
• Tan DSP, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. J Gynecol Oncol 2021; 32(2):e27. 
• Kwek JW, Chan JJ, Kanesvaran R, Wang MLC, Neo PSH, Chia CS, Tham CK, Chew LST, Tan HK, Yap SP, Dent RA, Hwang WYK, Lim ST. Early outcomes of a national cancer cen-ter's strategy against COVID-19 executed through a disease outbreak response taskforce. JCO Oncol Practice 2021; 17(3):e343-54. 
• Chan JJ, Tan TJY, Dent RA. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. Curr Opin Oncol 2020; 32(6):575-84. 
• Chan JJ, Sim Y, Ow SGW, Lim JSJ, Kusumawidjaja G, Zhuang Q, Wong RX, Wong FY, Tan VKM, Tan TJY. The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocr Relat Cancer 2020; 27(9):R307-27. 
• Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol 2019; 11:1758835919880429. 
• Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and meta-analysis of the association be-tween BDNF Val66Met polymorphism and cognitive impairment in patients receiving chemotherapy. Mol Neurobiol 2019; 56(7):4741-50. 
• Chan JJ, Tan TJY, Dent RA. Are there any clinically relevant subgroups of triple-negative breast cancer in 2018? J Oncol Pract 2018; 14(5):281-9.